NKTR - Nektar Therapeutics GAAP EPS of -$0.32 beats by $0.13 revenue of $22.02M misses by $0.19M
- Nektar Therapeutics press release ( NASDAQ: NKTR ): Q4 GAAP EPS of -$0.32 beats by $0.13 .
- Revenue of $22.02M (-12.0% Y/Y) misses by $0.19M .
- Cash and investments in marketable securities at December 31, 2022, were approximately $505.0 million as compared to $798.8 million at December 31, 2021.
- Shares +3.62% AH.
For further details see:
Nektar Therapeutics GAAP EPS of -$0.32 beats by $0.13, revenue of $22.02M misses by $0.19M